Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Skye Bioscience, Inc. (SKYE) had Weighted-Average Shares Outstanding (Diluted) of 39.65M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-11.10M |
|
-- |
|
-- |
|
$11.76M |
|
$-11.76M |
|
$0.66M |
|
$-11.10M |
|
$-11.10M |
|
$-11.10M |
|
$-11.10M |
|
$-11.10M |
|
$-11.10M |
|
$-11.76M |
|
$-11.58M |
|
39.65M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
39.65M |
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$63.03M |
|
$1.30M |
|
$1.77M |
|
$64.79M |
|
$5.32M |
|
-- |
|
$0.22M |
|
$5.54M |
|
$59.25M |
|
$59.25M |
|
$59.25M |
|
30.98M |
|
| Cash Flow Statement Financials | |
$-9.19M |
|
$-12.81M |
|
$0.00M |
|
$68.42M |
|
$46.42M |
|
$-21.99M |
|
$2.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.19M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.74% |
|
-18.74% |
|
-17.14% |
|
-18.74% |
|
$1.91 |
|
$-0.23 |
|
$-0.23 |
|